A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
Alzheimer's Disease
About this trial
This is an interventional treatment trial for Alzheimer's Disease
Eligibility Criteria
Inclusion Criteria: Completion of the Planned Treatment Period in the AL002-2 study. The participant is willing and able to give informed consent. Study partner who consents to study participation and who cares for/visits the participant at least 10 hours a week Exclusion Criteria: Participants deemed not able to provide consent or assent by the Investigator or by local regulations. Participants who were prematurely and permanently discontinued from treatment in the parent study for safety reasons. Participation deemed inappropriate per Investigator discretion.
Sites / Locations
- Charter ResearchRecruiting
- Hattiesburg ClinicRecruiting
- Advanced Clinical InstituteRecruiting
- Summit Research NetworkRecruiting
- KaRa Institute of Neurological DiseaseRecruiting
- Box Hill HospitalRecruiting
- ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia - INCIPIT - PINRecruiting
- NZOZ Wroclawskie Centrum AlzheimerowskieRecruiting
- Centrum Medyczne NeuroProtect
- EUROMEDIS Sp. z o.o.Recruiting
- Hospital de La Santa Creu i Sant PauRecruiting
- Fundacion ACE Instituto Catalan de Neurociencias-Gran via de Carles III, 85 bisRecruiting
- Hospital Universitario Doctor PesetRecruiting
- Hospital Viamed Montecanal
- Re:Cognition Health
- The National Hospital for Neurology and Neurosurgery
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
AL002 Dose 1
AL002 Dose 2
AL002 Dose 3
AL002 every 4 weeks
AL002 every 4 weeks
AL002 every 4 weeks